Livingstone Health Holdings Ltd (PRH) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Livingstone Health Holdings Ltd S$0.02, price S$0.02, upside -11.3%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Livingstone Health Holdings Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range 0.0150 SGD – 0.1880 SGD · the 0.0240 SGD price screens above the 0.0213 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Livingstone Health Holdings in your weekly email
Every Wednesday you see whether Livingstone Health Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Livingstone Health Holdings Limited, an investment holding company, provides medical treatment and consultancy services in Singapore. It operates through three segments: Specialist Healthcare, Primary Healthcare, and Others.
Show more
Livingstone Health Holdings Limited, an investment holding company, provides medical treatment and consultancy services in Singapore. It operates through three segments: Specialist Healthcare, Primary Healthcare, and Others. The Specialist Healthcare segment offers medical services in anaesthesiology and pain management; orthopaedic surgery; dermatology; and internal medicine fields, as well as endocrinology services. The Primary Healthcare segment is involved in the provision of vaccination and general medicine services; and the management of general acute conditions, such as respiratory/gastrointestinal infections, musculoskeletal complaints, headaches, and dermatological conditions, as well as chronic conditions comprising diabetes, hypertension, dyslipidaemia, and asthma. The Other segment provides aesthetics and wellness, podiatry, nerve testing, and consultancy function solutions. This segment also engages in the management of healthcare solutions and provision of management services. It offers its services through a network of primary care clinics, private medical specialists, and allied health care professionals. The company was founded in 2015 and is headquartered in Singapore.
Stock analysis
Livingstone Health Holdings Ltd (PRH) currently trades at 0.0240 SGD, while our model-based Fair Value estimate is 0.0213 SGD, 11.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 0.0600 SGD per share, and 12 of the 18 models we run sit above the 0.0240 SGD price.
Bear case: the Multiples group reads lowest at 0.0100 SGD, and 6 of the 18 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Livingstone Health Holdings Ltd reported revenue of 29.3M SGD in FY2025 versus 34.1M SGD in FY2021, a compound −3.8%/yr. Reported net income was 223K SGD in FY2025, compounding −47.9%/yr from FY2021.
Key figures
Market cap 16.4M SGD (≈ $12.8M) · P/S ratio 0.56 · Net margin 0.8% · Return on equity −10.5% · Return on assets (EBIT) 5.1% · Operating margin −3.1% · Revenue (TTM) 29.3M SGD · Revenue growth (YoY) +1.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −11%, PRH screens richer than that median.
Fair Value models
Bear 0.0213 SGDFair Value 0.0213 SGDBull 0.0213 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+5.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.6%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.8%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−40.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−40.7%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → −1%
⚠ Revenue per share shrinking 35.8%/yr over ~6Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−16.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about −17.8% a year for the price.
Compare Livingstone Health Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−11.3% · Below median
Profitability
Return on assets−0.4% · Bottom 25%
Net margin (TTM)0.8% · Bottom 25%
Operating margin (TTM)−3.1% · Bottom 25%
Growth and dividend
Revenue growth1.9% · Below median
Balance sheet
Debt / equity0.22× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Livingstone Health Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/PRH
Frequently asked questions
Is Livingstone Health Holdings Ltd (PRH) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of 0.0213 SGD versus a price of 0.0240 SGD, about −11% upside (overvalued).
What is the fair value of PRH?
Our model-based fair value for Livingstone Health Holdings Ltd is 0.0213 SGD (as of Sep 27, 2026), built from audited fundamentals. The current price: 0.0240 SGD.
What is the quality score of PRH?
Livingstone Health Holdings Ltd has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Livingstone Health Holdings Ltd (PRH)?
Our model-based price target is the fair value of 0.0213 SGD (as of Sep 27, 2026) from 19 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Livingstone Health Holdings Ltd stock forecast for 2026?
Our models put fair value at 0.0213 SGD, about −11% upside versus a price of 0.0240 SGD (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Livingstone Health Holdings Ltd (PRH)?
Livingstone Health Holdings Ltd reported trailing-twelve-month revenue of about 29.3M SGD (latest available figure, as of Sep 27, 2026).
What growth is priced into Livingstone Health Holdings Ltd (PRH)?
For today's price to be fair in a discounted-cash-flow model, Livingstone Health Holdings Ltd would have to grow free cash flow by -16.2 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.6 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of PRH use?
Our models discount Livingstone Health Holdings Ltd at 8.3 %: a base by market capitalisation (nano), damped by beta 0.42, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Livingstone Health Holdings Ltd that is -16.2 % per year a year over ten years, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has Livingstone Health Holdings Ltd (PRH) delivered so far?
Over the past 5 years revenue at Livingstone Health Holdings Ltd grew +10.6 % a year. The price currently implies -16.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Livingstone Health Holdings Ltd (PRH) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Livingstone Health Holdings Ltd (-16.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Livingstone Health Holdings Ltd (PRH)?
The free-cash-flow yield on the price is 18.41 %: that much free cash flow Livingstone Health Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Livingstone Health Holdings Ltd (PRH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Livingstone Health Holdings Ltd it is 0.0213 SGD per share (as of Sep 27, 2026), against a price of 0.0240 SGD. It is the blended result of 19 valuation models (cash flow, earnings, asset, dividend).
Is Livingstone Health Holdings Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, PRH trades above its calculated fair value: price 0.0240 SGD, fair value 0.0213 SGD, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRH?
No. The price is what the market pays today (0.0240 SGD); the fair value is what the company's own numbers justify (0.0213 SGD). For Livingstone Health Holdings Ltd the two are 0.0027 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is Livingstone Health Holdings Ltd worth?
The market values Livingstone Health Holdings Ltd at about 16.4M SGD (market capitalisation, as of Sep 27, 2026). Per share that is 0.0240 SGD; our models calculate a fair value of 0.0213 SGD per share.
How solid is the balance sheet of Livingstone Health Holdings Ltd (PRH)?
Balance-sheet figures for Livingstone Health Holdings Ltd (as of Sep 27, 2026): return on equity −10.5%, debt of 0.22 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is PRH from its 52-week high?
Livingstone Health Holdings Ltd trades at 0.0240 SGD, about 27% below its 52-week high of 0.0330 SGD and 4% above the low of 0.0230 SGD (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0213 SGD is for.
Which stocks are comparable to Livingstone Health Holdings Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Livingstone Health Holdings Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price 0.0240 SGD, calculated fair value 0.0213 SGD (−11%), Quality Score 48/100, from 19 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PRH calculated?
We run Livingstone Health Holdings Ltd through 19 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0213 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Livingstone Health Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Livingstone Health Holdings Ltd (PRH)?
The closing price on Oct 2, 2026 was 0.0240 SGD. Our model-based fair value is 0.0213 SGD, about −11% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Livingstone Health Holdings Ltd right now?
The price sits above even our optimistic bull case (0.0213 SGD). The favourable scenario is already priced in. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Livingstone Health Holdings Ltd
How large is the market capitalisation of Livingstone Health Holdings Ltd (PRH)?
The market capitalisation of Livingstone Health Holdings Ltd is 16.4M SGD (≈ $12.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Livingstone Health Holdings Ltd (PRH)?
The price-to-sales ratio of Livingstone Health Holdings Ltd is 0.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Livingstone Health Holdings Ltd (PRH)?
The net margin of Livingstone Health Holdings Ltd is 0.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Livingstone Health Holdings Ltd (PRH)?
The return on equity (ROE) of Livingstone Health Holdings Ltd is −10.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Livingstone Health Holdings Ltd (PRH)?
On an EBIT basis the return on assets of Livingstone Health Holdings Ltd is 5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Livingstone Health Holdings Ltd (PRH)?
The operating margin of Livingstone Health Holdings Ltd is −3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Livingstone Health Holdings Ltd (PRH)?
Revenue at Livingstone Health Holdings Ltd is growing +1.9% versus a year earlier (3y avg −3.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Livingstone Health Holdings Ltd (PRH)?
Earnings per share at Livingstone Health Holdings Ltd are growing +58.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Livingstone Health Holdings Ltd (PRH) carry?
The net debt of Livingstone Health Holdings Ltd is 539K SGD (fiscal year 2025, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Livingstone Health Holdings Ltd in the live analysis
One click puts Livingstone Health Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
